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Electroconvulsive seizures (ECS) do not
prevent LPS-induced behavioral alterations
and microglial activation
E. M. van Buel1,3 , F. J. Bosker2, J. van Drunen1, J. Strijker1, W. Douwenga1, H. C. Klein2,3 and U. L. M. Eisel1,2*
Abstract
Background: Long-term neuroimmune activation is a common finding in major depressive disorder (MDD).
Literature suggests a dual effect of electroconvulsive therapy (ECT), a highly effective treatment strategy for MDD,
on neuroimmune parameters: while ECT acutely increases inflammatory parameters, such as serum levels of
pro-inflammatory cytokines, there is evidence to suggest that repeated ECT sessions eventually result in
downregulation of the inflammatory response. We hypothesized that this might be due to ECT-induced attenuation
of microglial activity upon inflammatory stimuli in the brain.
Methods: Adult male C57Bl/6J mice received a series of ten electroconvulsive seizures (ECS) or sham shocks,
followed by an intracerebroventricular (i.c.v.) lipopolysaccharide (LPS) or phosphate-buffered saline (PBS) injection.
Brains were extracted and immunohistochemically stained for the microglial marker ionized calcium-binding
adaptor molecule 1 (Iba1). In addition, a sucrose preference test and an open-field test were performed to quantify
behavioral alterations.
Results: LPS induced a short-term reduction in sucrose preference, which normalized within 3 days. In addition,
LPS reduced the distance walked in the open field and induced alterations in grooming and rearing behavior. ECS
did not affect any of these parameters. Phenotypical analysis of microglia demonstrated an LPS-induced increase in
microglial activity ranging from 84 to 213 % in different hippocampal regions (CA3 213 %; CA1 84 %; dentate gyrus
131 %; and hilus 123 %). ECS-induced alterations in microglial activity were insignificant, ranging from −2.6 to
14.3 % in PBS-injected mice and from −20.2 to 6.6 % in LPS-injected mice.
Conclusions: We were unable to demonstrate an effect of ECS on LPS-induced microglial activity or behavioral
alterations.
Keywords: ECS, Depression-like behavior, LPS, Inflammation, Microglia
Background
Electroconvulsive therapy (ECT) is a highly effective
clinical treatment strategy for major depressive disorder
(MDD). Multiple studies have shown superior efficacy for
ECT compared to pharmaceutical treatment strategies [1].
Over the past decades, numerous studies have been pub-
lished that have attempted to unravel the neurobiological
mechanisms behind the antidepressant effects of ECT.
These studies have resulted in a rapid increase in the un-
derstanding of these mechanisms, with one of the most
consistent findings being a strong effect on neurogenesis
accompanied by increased levels of neurotrophic factors
[2–16]. Nevertheless, many questions remain unanswered.
Long-term neuroimmune activation is a common find-
ing in MDD. MDD is associated with elevated levels of
pro-inflammatory cytokines and decreased levels of anti-
inflammatory cytokines [17]. In addition, there is evidence
for altered functionality of immune cells, including in-
creased activity of microglia, the resident immune cells of
the brain [18]. Literature suggests that antidepressant
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treatment may, at least in part, normalize neuroimmune
changes associated with MDD [19–21].
Although literature on the effects of ECT on neuroim-
mune parameters is relatively scarce, the available litera-
ture points towards a dual effect: while ECT acutely
increases inflammatory parameters, repeated ECT sessions
eventually result in a downregulation of the inflammatory
response [22–25]. For example, although acute ECT upre-
gulates serum levels of pro-inflammatory cytokines such
as TNFα, IL-1β, and IL-6 in MDD patients [22–24], serum
TNFα levels gradually decrease over the course of mul-
tiple ECT sessions until they eventually reach levels within
the range of healthy control subjects [22]. In addition,
animal studies have provided evidence for acute transient
microglia activation upon electroconvulsive seizures (ECS;
an animal model for ECT) [26].
Based on these findings, we hypothesized that repeated
ECT sessions suppress the activation of resident immune
cells upon inflammatory stimuli in the brain. This might
explain the downregulation of inflammatory parameters
and clinical improvement as observed in successfully
treated MDD patients. To test this hypothesis, we ex-
posed mice that had received a series of ECS to a
pro-inflammatory stimulus (an intracerebroventricular
lipopolysaccharide injection) inducing depressive-like
behavior. We assessed the extent of microglia activation in
the hippocampus upon this inflammatory stimulus with
an ionized calcium-binding adaptor molecule 1 (Iba1) im-
munohistochemical staining. In addition, behavioral tests
were performed to investigate whether ECS could prevent
behavioral alterations associated with inflammation.
Methods
Animals
Three-month-old male C57Bl/6J mice were obtained
from Janvier. Animals were housed in individual cages
under standardized conditions (temperature 21 ± 2 °C,
humidity 50–60 %, 12:12 h light/dark cycle). Food and
water were available ad libitum. Animals were handled
for at least 1 week prior to the start of the experiment.
Throughout the experiment, body weight was measured
on a daily basis. The Ethical Committee for the Use of
Experimental Animals of the University of Groningen
had approved all experiments (DEC6229G).
Experimental design
Figure 1 shows the experimental design that was followed
during this study. Mice (n = 40) were equally divided
across four groups (PBS + sham, PBS + ECS, LPS + sham,
and LPS + ECS). A sucrose preference test was started
6 days prior to the first ECS treatment and was continued
throughout the experiment. ECS or sham ECS was per-
formed daily for 10 days. Lipopolysaccharide (LPS) or
phosphate-buffered saline (PBS) injections were delivered
1 day after the last ECS/sham treatment. Three days after
the LPS/PBS injections, an open-field test was performed
and mice were sacrificed. In previous experiments, this
timepoint was associated with maximal neuroinflamma-
tion [27].
Electroconvulsive seizures
Mice received a series of one electroconvulsive or sham
treatment per day for 10 days. Mice were anesthetized
with sevoflurane, and electroconvulsive shocks were deliv-
ered via ear clip electrodes using a pulse generator (Ugo
Basile, Comerio, Italy), set at the following shock parame-
ters: 80 mA, 50 Hz, 1 s duration, and 0.5 ms pulse width.
All mice developed tonic-clonic seizures lasting approxi-
mately 10–15 s, which is comparable to the seizure dur-
ation induced by electroconvulsive seizures (ECS) in other
experiments [28–30]. The total duration of anesthesia was
approximately 5 min per mouse. Mice in the sham groups
underwent the same procedure, including sevoflurane
anesthesia and placement of the ear clip electrodes, with-
out delivery of the electroconvulsive shock.
Intracerebroventricular LPS injections
Mice were anesthetized with sevoflurane and fixated in a
stereotact. Analgesia was provided via a subcutaneous
injection of 2.5 mg/kg finadyne. A skin incision was
made to expose the skull, and holes were drilled perpen-
dicularly to the skull. Mice were injected with 1 μl PBS
or 1 μl 5 mg/ml LPS (l-6529, serotype 055:B5, Sigma-
Aldrich) in PBS at the following coordinates: −2.5 mm
Fig. 1 Experimental design. Daily ECS/sham procedures were performed for 10 days, followed by one single LPS or PBS injection. Three days after
the LPS or PBS injection, an open-field test was performed and the mice were sacrificed. A sucrose preference test was started 6 days prior to the
first ECS/sham procedure and continued for the entire duration of the experiment
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dorsal/ventral, −1.0 mm lateral, and −0.5 mm anterior/
posterior from bregma. Injections were performed at a
constant rate of 0.3 μl/min using a syringe pump (TSE
Systems, Bad Homburg, Germany) in combination with
a 25-μl Hamilton syringe connected to a 1-μl Hamilton
needle (cat. nr.170431, Omnilabo). The needle was not
removed from the brain until 5 min after the injection
to prevent any leakage of LPS via the injection canal.
The holes were sealed with dental cement, and the inci-
sion was closed with sutures.
Sucrose preference test
Mice were given a choice between two drinking pipettes,
one containing normal drinking water and the other
containing a 0.5 % sucrose solution. Mice had access to
both pipettes 24 h per day. Water and sucrose intake
were measured on a daily basis. The relative location of
both pipettes was switched on a daily basis to avoid
place preference. Mice that showed such a place prefer-
ence and therefore failed to develop a consistent prefer-
ence for sucrose were excluded from subsequent analysis.
Open-field test
Mice were placed in a round arena with a diameter of
50 cm consisting of two zones: a border zone adjacent
to the wall of the arena and an inner zone in the center
of the arena. Mice were allowed to explore their sur-
roundings freely for 7 min. All experiments were re-
corded by an overhead camera. Distance moved and
time spent in the different zones were scored using
EthoVision software (Noldus Information Technology,
Wageningen, Netherlands). An observer blinded to the
treatment scored grooming and rearing behavior manually.
Iba1 immunohistochemistry
Mice (n = 6 per group) were transcardially perfused with
a saline solution containing 0.5 % heparin followed by a
4 % paraformaldehyde (PFA) solution in 0.1 M phos-
phate buffer. Brains were removed and postfixated for
24 h in 4 % PFA in 0.1 M PBS, followed by 18 h in a
30 % sucrose solution for cryoprotection. Brains were
frozen using liquid nitrogen and cut into sections of
20 μm. A DAB staining for the microglial marker Iba1
was performed on free-floating hippocampal and pre-
frontal cortex (PFC) sections. Sections were incubated
for 72 h with primary antibody (rabbit anti-Iba1, Wako
Chemicals, Neuss, Germany) diluted 1:2500 in 0.01 M
PBS (pH 7.4) containing 1 % bovine serum albumin
(BSA) and 0.1 % triton X-100. Subsequently, sections
were incubated with secondary antibody (1:500; goat
anti-rabbit, Jackson ImmunoResearch, Suffolk, UK) for
2 h, followed by a 1-h incubation with avidin-biotin
complex (1:500; Vector Laboratories Burlingame, CA,
USA). Finally, 0.075 mg/ml DAB was added and the
DAB reaction was initiated with 100 μl 0.1 % H2O2. Sec-
tions were carefully rinsed with 0.01 M PBS between all
steps of the protocol, and all antibodies and chemicals
were diluted in 0.01 M PBS unless stated otherwise.
Microglial activation was measured with Image-Pro
software (Image-Pro Plus 6.0.0.26, Media Cybernetics,
Inc. Rockville, USA) using a method described by Hovens
et al. [31]. In short, photographs were taken at ×100 mag-
nification. The software first automatically determined the
total coverage of the microglia cells (cell bodies and pro-
cesses). Subsequently, intensity and size thresholds were
changed in such a way that only the coverage of the cell
bodies was measured. The cell bodies to total coverage
ratio was calculated. This ratio was shown to accurately
reflect activation state in previous experiments [31]. In
addition, the number of cells was counted manually.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism 5.0 (GraphPad Software, San Diego, CA, USA).
Most data was statistically analyzed using a two-way
ANOVA to calculate p values for the main effects of
group (LPS/PBS) and treatment (ECS/sham) and the
group × treatment interaction effect. Body weight was
analyzed via a repeated measures ANOVA with post hoc
Bonferroni test. Data are presented as mean ± standard
error.
Results
LPS decreases body weight
Figure 2 shows body weight as a percentage of baseline
body weight (measured on day 0 prior to the first ECS/
sham session; see also Additional file 1). Body weight
was not significantly influenced by ECS treatment. How-
ever, intracerebroventricular (i.c.v.) LPS injections re-
sulted in a marked decrease in body weight in both the
ECS and sham groups. Body weight partly normalized
3 days after LPS injection. This is in line with previous
experiments that showed that body weight is decreased
up to 3 days after LPS injection [27]. I.c.v. PBS injection
did not result in significant alterations in body weight.
LPS acutely decreases sucrose preference
Figure 3a shows sucrose preference over the entire dur-
ation of the experiment (see also Additional file 2). Dur-
ing the habituation phase prior to the start of the ECS
sessions, sucrose preference gradually increased to around
80 %. Sucrose preference was not influenced by electro-
convulsive seizures. I.c.v. LPS injections caused a tempor-
ary decrease in sucrose preference in both the ECS and
sham groups, which fully normalized 3 days after injec-
tion. An area under the curve (Fig. 3b, Additional file 2)
was calculated for the time between LPS injection and the
end of the experiment (days 10–13; the gray area in a).
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Fig. 3 Sucrose preference. a Sucrose preference is presented as a percentage of total fluid intake over 24 h. ECS/sham sessions were performed
daily from day 0 to day 9. I.c.v. LPS/PBS injections were performed on day 10. b An area under the curve (AUC) was calculated for days 10–13
(the gray area in a). There was a significant main effect for group (PBS/LPS; p = 0.0405) but not for treatment (sham/ECS) or group × treatment
interaction (two-way ANOVA)
Fig. 2 Body weight. Body weight is presented as a percentage of baseline body weight (measured prior to the first ECS session on day 0). ECS/sham
sessions were performed daily from day 0 to day 9. I.c.v. LPS/PBS injections were performed on day 10. *p < 0.05; **p < 0.01; ***p < 0.001 compared
to sham + PBS
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The area under the curve (AUC) was analyzed via a two-
way ANOVA, demonstrating a significant main effect for
group (LPS/PBS; p = 0.0405). No significant effects were
found for treatment or treatment × group interaction
(p = 0.7372 and p = 0.4808, respectively).
Both LPS and ECS influence behavior in the open-field test
Distance moved and time spent in the border zone of
the arena (Fig. 4a, b; Additional file 3) were scored auto-
matically. LPS decreased the total distance moved during
the test regardless of electroconvulsive seizures (main ef-
fect for group: p = 0.0361). No significant effects were
observed for sham/ECS treatment and treatment × group
interaction (p = 0.4525 and p = 0.9956, respectively).
The time spent in the border zone was significantly in-
creased in the ECS groups (main effect for sham/ECS
treatment: p = 0.005). No significant differences were
observed for the PBS/LPS group effect and the treat-
ment × group interaction effect (p = 0.6323 and p = 0.4739,
respectively).
Grooming and rearing behavior (Fig. 4c, d; Add-
itional file 3) were scored manually. In both the ECS
and sham groups, LPS increased grooming behavior
(main effect for group: p = 0.0334) but decreased rearing
behavior (main effect for group: p = 0.0159). The main ef-
fect for sham/ECS treatment and the treatment × group
interaction effect were not significant for either behavior
(grooming: p = 0.3702 and p = 0.2830, respectively; rear-
ing: p = 0.1126 and p = 0.9521, respectively).
ECS does not prevent LPS-induced microglial activity
The depression-like behavioral effects of LPS are believed
to be related to their inflammatory effects. Here, we were
interested in the effect of ECS on LPS-induced inflamma-
tory changes in the brain. Therefore, we measured the ra-
tio of the microglia cell bodies to the total coverage of cell
bodies and processes. As activated microglia undergo a
conformational change towards shorter and thicker pro-
cesses and increased size of the cell bodies, this ratio re-
flects the level of microglial activity [31].
Fig. 4 Open-field test. Three days after PBS/LPS injection, an open-field test was performed. The graphs represent a distance moved during the
test, b percentage of time spent in the border zone of the arena, c percentage of time spent grooming, and d percentage of time spent rearing.
There was a significant main effect for group (PBS/LPS) on the distance moved during the test (a; p = 0.0361), percentage of time spent grooming
(b; p = 0.0334), and percentage of time spent rearing (d; p = 0.0159). In addition, a significant main effect for treatment (sham/ECS) was found for
the percentage of time spent in the border zone (b; p = 0.005). Other main effects did not reach significance, and interaction effects were not
significant for any of these parameters
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Representative pictures of Iba1-stained microglia in
the hilus, CA1, and CA3 regions of the hippocampus are
shown in Fig. 5. Figure 6 presents microglial activity in
the different hippocampal areas (see also Additional file
4). In the sham groups, LPS increased microglial activity
by 84 to 213 % in different hippocampal areas (CA3
213 %; CA1 84 %; dentate gyrus 131 %; and hilus 123 %).
ECS altered microglial activity by −2.6 to 14.3 % in PBS-
injected mice (CA3 1.6 %; CA1 −2.6 %; dentate gyrus
5.4 %; and hilus 14.3 %) and by −20.2 to 6.6 % in
LPS-injected mice (CA3 −20.2 %; CA1 6.6 %; dentate
gyrus 2.6 %; hilus −8.8 %; compared to the sham+ LPS
group). In all areas that were analyzed (CA1, CA3, hilus,
and dentate gyrus), there was a highly significant main
effect for group (p < 0.0001 for all areas) but not for treat-
ment (CA3: p = 0.2708; CA1: p = 0.6038; dentate gyrus:
p = 0.6610; hilus: p = 0.8269). The group × treatment
interaction effect was not significant for any of the hippo-
campal regions (CA3: p = 0.2468; CA1: p = 0.4246; dentate
gyrus: p = 0.9815; hilus: p = 0.2318).
In addition to microglial activity, the number of micro-
glia was counted in each hippocampal area (Fig. 7,
Additional file 4). LPS induced an increase in the number
of microglia in all hippocampal areas (main effect for LPS/
PBS: p < 0.0001 for the CA3 and the hilus, p = 0.0336 for
the CA1, and p = 0.0002 for the dentate gyrus). Again,
ECS did not affect the number of microglia and there was
no significant interaction effect (CA3: p = 0.7831 and p =
0.5466, respectively; CA1: p = 0.3027 and p = 0.3606,
respectively; dentate gyrus: p = 0.3508 and p = 0.3046,
respectively; hilus: p = 0.6494 and p = 0.8480, respectively).
Discussion
The goal of this study was to investigate whether re-
peated ECS sessions suppress the activation of microglia
after an inflammatory challenge of the brain. We showed
that ECS does not significantly reduce behavioral effects
nor microglial activation after an LPS challenge. In con-
trast, literature indicates that effective repeated ECT
treatment in patients may result in normalization of
serum levels of cytokines such as TNF-alpha [22, 32].
The dose of LPS was chosen based on its ability to in-
duce depression-like behavior in previous experiments
[27]. However, the extreme microglial activation ob-
served in the LPS groups suggests that the inflammatory
effects of LPS in this study may not be comparable to
the inflammatory alterations in MDD patients, which
are possibly relatively mild and could have a more pro-
longed nature [33]. Therefore, we cannot exclude that
the inflammatory and behavioral effect of LPS injection
Fig. 5 Iba1 immunohistochemistry. Three days after PBS/LPS injection, mice were sacrificed, and brain sections were immunohistochemically
stained for the microglial marker Iba1. This figure shows representative pictures of Iba1 stained microglia for three hippocampal areas (hilus, CA1,
and CA3) and four treatment groups (sham + PBS, ECS + PBS, sham + LPS, and ECS + LPS)
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might be too strong to be significantly reduced by ECS
treatment.
One should also keep in mind that the mechanisms
involved in the relatively short-term inflammatory re-
sponse induced by LPS might differ substantially from
those involved in the more long-term, low-grade inflam-
mation associated with MDD. Therefore, the nature of
the inflammatory response in this study may be quite
different from the nature of inflammation associated with
clinical depression. Indeed, although there is a substantial
overlap in the physiological parameters associated with
MDD and LPS-induced depression-like behavior, there
are also several differences, for example in the relative
contribution of certain types of cytokines [34]. Although
previous experiments in the same department had dem-
onstrated depression-like behavior up to 4 days after i.c.v.
LPS injection [27], the sucrose preference data presented
in this study suggest that depression-like behavior normal-
izes within 3 days after LPS injection. This inconsistency
might be due to methodological differences. While Dobos
et al. [27] assessed depression-like behavior via a forced
swim test; we have chosen to perform a sucrose prefer-
ence test as this test allows for repeated measurements.
Most LPS studies have focused on the short-term ef-
fects of LPS on behavior (several hours to 2 days after
injection); several studies have investigated longer-term
effects of LPS, although these studies have employed
peripheral intraperitoneal LPS injections instead of cen-
tral injections. The majority of these studies indicate that
the effects of LPS on depressive-like behavior in the
sucrose preference test [35], forced swim test [36, 37], or
tail suspension test [38] are transient in healthy adult
rodents, normalizing within 24–72 h. These studies are
in line with the results of this study, demonstrating de-
creased sucrose preference that normalizes within 72 h.
Painsipp et al. [39], however, have found increased im-
mobility in the forced swim test and decreased sucrose
preference up to 4 weeks after LPS injection in C57Bl/6
mice but not CD-1 mice. This shows that the effects of
LPS may be dependent upon the animal and strain used
in the experiment. In addition, differences in the sero-
type and concentration of LPS used for injection may
Fig. 6 Microglia activation. Microglia activation is reflected by the ratio of the coverage of the cell bodies to the total coverage (cell bodies and
processes). Data are given as percentages of the sham + PBS group. a Microglia activation in the CA3 area of the hippocampus. b Microglia activation
in the CA1 area of the hippocampus. c Microglia activation in the hippocampal dentate gyrus. d Microglia activation in the hippocampal hilus. In all
areas, a highly significant main effect for group (LPS/PBS) was found (p < 0.0001 for all areas). The main effects for treatment (sham/ECS) and group ×
treatment interaction effects did not reach significance for any of the analyzed brain areas
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have contributed to the discrepancies between these
studies.
Several attempts have been made to induce a more
chronic type of inflammation in rodents. For example,
recent studies demonstrate that repeated peripheral LPS
injections in rodents can induce microglial activation,
prolonged depression-like behavior, and expression of a
specific pattern of cytokines [40–42]. Although deter-
mination of the optimal dose and frequency of LPS
injection requires further research, this method of indu-
cing inflammation may be more comparable to the
pathophysiology of depression. In addition, stress-related
depression models, such as the chronic unpredictable
mild stress model and the chronic social defeat stress
model, are well known to increase the levels of certain
inflammatory parameters, including pro-inflammatory
cytokines and microglial activity [43–45]. It would thus
be interesting to study the effects of ECS on inflamma-
tory parameters in such models.
It is important to note that in this study, we have in-
vestigated the ability of ECS to suppress the reactivity of
microglial cells towards inflammatory stimuli. Thus, we
have given ECS prior to LPS injection. Therefore, we
cannot draw conclusions regarding the ability of ECS to
reduce microglial activity in case of pre-existing neuroim-
mune activation. Thus, it is possible ECS may reduce
pre-existing neuroimmune activation without affecting
microglial reactivity to inflammatory stimuli administered
post-ECS.
The involvement of microglia in MDD pathophysi-
ology is confirmed by a recent PET study investigating
translocator protein (TSPO) binding as a biomarker for
microglial activity in MDD patients with an active major
depressive episode [46]. Microglial activity was found to
be increased in various brain areas, including the hip-
pocampus. Moreover, this increase correlated with the
severity of depression.
Conclusions
With the read out parameters chosen here, this study
suggests that ECS does not have a suppressive effect on
microglia activation in an inflammatory depression model,
Fig. 7 Quantification of microglia. Microglia were counted manually. The graphs show the number of microglia per square millimeter in the
following hippocampal areas: CA3 (a), CA1 (b), dentate gyrus (c), and hilus (d). In all areas, a significant main effect for group (LPS/PBS) was found
(p < 0.0001 for the CA3 and the hilus, p = 0.0336 for the CA1, and p = 0.0002 for the dentate gyrus). The main effects for treatment (sham/ECS)
and group × treatment interaction effects did not reach significance for any of the analyzed brain areas
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which is possibly due to the rather powerful challenge
with intracerebral LPS injection. This does not rule out
that inflammatory states in milder depression models
might be effectively reduced by ECS.
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